Last reviewed · How we verify
NCT07093385
Intravitreal Faricimab in Patients With Refractory Macular Edema
Phase 2 trial testing Faricimab Injection in Age-Related Macular Degeneration in 43 participants. Completed in 1 July 2025.
1 June 2025
Quick facts
| Lead sponsor | University of Baghdad |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 10 September 2024 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Faricimab Injection — full drug profile →
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
Sponsor
University of Baghdad
Who can join
Adults 45 to 90, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective study will include about 40 patients with resistant wet age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion edema (RVO) edema.The inclusion criteria are that all patients must be 40 years old or older, diagnosed with active wet AMD or macular edema due to RVO or DME, and have received at least four previous monthly injections of anti-VEGF other than faricimab. All patients will be switched to receive four loading doses of intravitreal faricimab (6 mg) at 4-week intervals for four months. The response to faricimab will be assessed regarding visual acuity and central macular thickness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of Intravitreal Faricimab in Patients with Refractory Macular Edema Secondary to Retinal Vein Occlusion, Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.
Al-Azzawi DJ, Muwafaq Alabdali S, Rajab Al-Alwsi Z. · · 2026 · DOI 10.12688/f1000research.178124.1
Verify or expand the search:
- PubMed search for NCT07093385
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other University of Baghdad trials
Trials by the same sponsor.
- NCT07417839 — (Effect of Toy Nebulizer Versus Distraction Cards on Children's Fear and Parental Satisfaction During Nebulization Thera · NA · not yet recruiting
- NCT07456657 — Effect of Lavender Aromatherapy Massage on Pain and Wrist Mobility in Rheumatoid Arthritis · NA · not yet recruiting
- NCT07460089 — Premature Infant Oral Motor Intervention vs. Pacifier for Oral Feeding Transition in Preterm Infants · NA · not yet recruiting
- NCT07350343 — The Predictability of Directly Printed Versus Thermoformed Clear Aligners · NA · enrolling by invitation
- NCT07362160 — Clear Orthodontic Expander Versus Hyrax · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07093385 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Baghdad
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07093385.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing